464 related articles for article (PubMed ID: 21470782)
1. F-18-FDG-PET confined radiotherapy of locally advanced NSCLC with concomitant chemotherapy: results of the PET-PLAN pilot trial.
Fleckenstein J; Hellwig D; Kremp S; Grgic A; Gröschel A; Kirsch CM; Nestle U; Rübe C
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e283-9. PubMed ID: 21470782
[TBL] [Abstract][Full Text] [Related]
2. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial.
Nestle U; Schimek-Jasch T; Kremp S; Schaefer-Schuler A; Mix M; Küsters A; Tosch M; Hehr T; Eschmann SM; Bultel YP; Hass P; Fleckenstein J; Thieme A; Stockinger M; Dieckmann K; Miederer M; Holl G; Rischke HC; Gkika E; Adebahr S; König J; Grosu AL;
Lancet Oncol; 2020 Apr; 21(4):581-592. PubMed ID: 32171429
[TBL] [Abstract][Full Text] [Related]
3. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer.
Bradley J; Thorstad WL; Mutic S; Miller TR; Dehdashti F; Siegel BA; Bosch W; Bertrand RJ
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):78-86. PubMed ID: 15093902
[TBL] [Abstract][Full Text] [Related]
4. FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer.
Thureau S; Dubray B; Modzelewski R; Bohn P; Hapdey S; Vincent S; Anger E; Gensanne D; Pirault N; Pierrick G; Vera P
Radiat Oncol; 2018 Oct; 13(1):208. PubMed ID: 30352608
[TBL] [Abstract][Full Text] [Related]
5. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
[TBL] [Abstract][Full Text] [Related]
6. 18F-FDG PET definition of gross tumor volume for radiotherapy of lung cancer: is the tumor uptake value-based approach appropriate for lymph node delineation?
Rodríguez N; Sanz X; Trampal C; Foro P; Reig A; Lacruz M; Membrive I; Lozano J; Quera J; Algara M
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):659-66. PubMed ID: 20133071
[TBL] [Abstract][Full Text] [Related]
7. Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?
Gillham C; Zips D; Pönisch F; Evers C; Enghardt W; Abolmaali N; Zöphel K; Appold S; Hölscher T; Steinbach J; Kotzerke J; Herrmann T; Baumann M
Radiother Oncol; 2008 Sep; 88(3):335-41. PubMed ID: 18514339
[TBL] [Abstract][Full Text] [Related]
8. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
9. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer.
Nestle U; Kremp S; Schaefer-Schuler A; Sebastian-Welsch C; Hellwig D; Rübe C; Kirsch CM
J Nucl Med; 2005 Aug; 46(8):1342-8. PubMed ID: 16085592
[TBL] [Abstract][Full Text] [Related]
10. Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer.
Deniaud-Alexandre E; Touboul E; Lerouge D; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Keraudy K; Kerrou K; Montravers F; Milleron B; Lebeau B; Talbot JN
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1432-41. PubMed ID: 16125870
[TBL] [Abstract][Full Text] [Related]
11. (18)F-FDG PET-CT simulation for non-small-cell lung cancer: effect in patients already staged by PET-CT.
Hanna GG; McAleese J; Carson KJ; Stewart DP; Cosgrove VP; Eakin RL; Zatari A; Lynch T; Jarritt PH; Young VA; O'Sullivan JM; Hounsell AR
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):24-30. PubMed ID: 19665324
[TBL] [Abstract][Full Text] [Related]
12. A clinical study of shrinking field radiation therapy based on (18)F-FDG PET/CT for stage III non-small cell lung cancer.
Ding X; Li H; Wang Z; Huang W; Li B; Zang R; Sun H; Yi Y
Technol Cancer Res Treat; 2013 Jun; 12(3):251-7. PubMed ID: 23289475
[TBL] [Abstract][Full Text] [Related]
13. Impact of [18F]fluorodeoxyglucose PET-CT staging on treatment planning in radiotherapy incorporating elective nodal irradiation for non-small-cell lung cancer: a prospective study.
Kolodziejczyk M; Kepka L; Dziuk M; Zawadzka A; Szalus N; Gizewska A; Bujko K
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1008-14. PubMed ID: 20656419
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
15. Current status of PET/CT for tumour volume definition in radiotherapy treatment planning for non-small cell lung cancer (NSCLC).
Greco C; Rosenzweig K; Cascini GL; Tamburrini O
Lung Cancer; 2007 Aug; 57(2):125-34. PubMed ID: 17478008
[TBL] [Abstract][Full Text] [Related]
16. Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy.
Dehing-Oberije C; De Ruysscher D; van der Weide H; Hochstenbag M; Bootsma G; Geraedts W; Pitz C; Simons J; Teule J; Rahmy A; Thimister P; Steck H; Lambin P
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1039-44. PubMed ID: 17889446
[TBL] [Abstract][Full Text] [Related]
17. FDG-PET/CT during concomitant chemo radiotherapy for esophageal cancer: Reducing target volumes to deliver higher radiotherapy doses.
Nkhali L; Thureau S; Edet-Sanson A; Doyeux K; Benyoucef A; Gardin I; Michel P; Vera P; Dubray B
Acta Oncol; 2015 Jun; 54(6):909-15. PubMed ID: 25417733
[TBL] [Abstract][Full Text] [Related]
18. An individualized radiation dose escalation trial in non-small cell lung cancer based on FDG-PET imaging.
Wanet M; Delor A; Hanin FX; Ghaye B; Van Maanen A; Remouchamps V; Clermont C; Goossens S; Lee JA; Janssens G; Bol A; Geets X
Strahlenther Onkol; 2017 Oct; 193(10):812-822. PubMed ID: 28733723
[TBL] [Abstract][Full Text] [Related]
19. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival.
Everitt S; Ball D; Hicks RJ; Callahan J; Plumridge N; Trinh J; Herschtal A; Kron T; Mac Manus M
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):947-955. PubMed ID: 29063854
[TBL] [Abstract][Full Text] [Related]
20. The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer.
Ashamalla H; Rafla S; Parikh K; Mokhtar B; Goswami G; Kambam S; Abdel-Dayem H; Guirguis A; Ross P; Evola A
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1016-23. PubMed ID: 15979817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]